Stocks Health care OBIO
NASDAQ · Health careOrchestra BioMed Holdings, Inc. (OBIO)
Orchestra BioMed Holdings, Inc. brought in $32M of revenue over the twelve months to June 30, 2026, up 986.1% from a year earlier. It posted a net loss of $59M. In fiscal 2025 capital spending exceeded operating cash flow by $49.5M. At June 30, 2026 it held $20.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 10, 2026.
Key facts about Orchestra BioMed Holdings, Inc.
- Net worth
- Orchestra BioMed Holdings, Inc. has a market value (market cap) of $344.4M at the latest share price, and shareholders' equity of $19.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $33.5M (+1,169.2% year on year), with a net loss of $52.7M. Over the 12 months to June 30, 2026: revenue $32M, net loss $59M.
- Cash flow
- In fiscal 2025 operations used $49M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 10, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Orchestra BioMed Holdings, Inc.'s next report was expected around November 9, 2026 and is not on file with the SEC yet.
What Orchestra BioMed Holdings, Inc. does
Orchestra BioMed Holdings, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker OBIO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $33.5M | -$52.7M | -$1.11 | -$49.5M |
| 2024 | $2.6M | -$61M | -$1.66 | -$50.8M |
| 2023 | $2.8M | -$49.1M | -$1.48 | -$46.2M |
| 2022 | $3.5M | -$33.6M | -$2.24 | -$29.9M |
| 2021 | n/a | -$378.8K | -$0.26 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where OBIO ranks in Health care
Dividends
It paid out $20M in cash dividends.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2022 | n/a | $20M | n/a |
Latest SEC filings
What Orchestra BioMed Holdings, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- October 1, 2026
- September 8, 2026
- August 10, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 89% to $88K versus the same quarter last year; diluted EPS -$0.38 versus -$0.50.
- June 23, 2026
- June 23, 2026
- June 16, 2026Additional proxy material DEFA14A
- May 12, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 87% to $110K versus the same quarter last year; diluted EPS -$0.33 versus -$0.49.
- April 29, 2026Activist stake changed SCHEDULE 13D/A
- April 29, 2026
Insider trades
What the people running Orchestra BioMed Holdings, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $288.6K and sold $255.6K worth of shares in the last 90 days. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 9, 2026 | Taylor Andrew LawrenceChief Financial Officer | Bought | 1,000 | $5K |
| November 9, 2026 | Hochman David PSee Remarks, Director | Boughtindirect | 5,000 | $25K |
| November 9, 2026 | Pacitti DavidDirector | Bought | 20,000 | $100K |
| November 9, 2026 | Fain Eric SDirector | Boughtindirect | 20,000 | $100K |
| November 2, 2026 | Sherman DarrenSee Remarks, Director | Soldpre-planned (10b5-1) | 15,000 | $86.1K |
| October 1, 2026 | Sherman DarrenSee Remarks, Director | Soldpre-planned (10b5-1) | 15,000 | $95.4K |
| September 10, 2026 | Hochman David PSee Remarks, Director | Shares withheld for tax | 3,283 | $19.1K |
| September 10, 2026 | Hochman David PSee Remarks, Director | Shares withheld for taxindirect | 3,283 | $19.1K |
Who owns OBIO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| RTW Investments, LP13D, may seek influence with 3 related filers | 19.2% | April 29, 2026 |
| Perceptive Advisors LLC13G, passive with 2 related filers | 9.99% | November 14, 2025 |
| Dana Lorenzo13G, passive with 1 related filers | 5.5% | November 19, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 77 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Rtw Investments, LP | 9,556,063 | +1,250,000 |
| Perceptive Advisors LLC | 5,037,906 | 0 |
| BlackRock, Inc. | 2,510,387 | +1,874,673 |
| Vanguard Capital Management LLC | 2,022,916 | -181,403 |
| Geode Capital Management, LLC | 1,007,908 | +522,416 |
| Alyeska Investment Group, L.P. | 1,000,000 | 0 |
| Propel Bio Management, LLC | 896,701 | 0 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 642,154 | new |
| State Street Corp | 516,050 | +346,640 |
| Rice Hall James & Associates, LLC | 424,000 | +404,999 |
| Charles Schwab Investment Management Inc | 349,544 | +84,045 |
| Northern Trust Corp | 343,640 | +225,366 |
| UBS Group AG | 325,773 | +275,463 |
| Vanguard Fiduciary Trust Co | 292,253 | +57,039 |
| Vanguard Portfolio Management LLC | 274,973 | new |
| Knott David M Jr | 253,651 | 0 |
| Flat Footed LLC | 251,372 | new |
| Simplify Asset Management Inc. | 219,387 | 0 |
| Goldman Sachs Group Inc | 179,606 | +24,364 |
| DAFNA Capital Management LLC | 126,841 | 0 |
Insiders
11 insiders reported holding 14,942,364 shares in total, about $85.6M at the last price.
| Holder | Shares |
|---|---|
| Rtw Investments, LP10% owner | 9,556,0639,556,063 held indirectly |
| Sherman DarrenSee Remarks, Director | 2,260,7292,000 held indirectly |
| Hochman David PSee Remarks, Director | 1,505,379437,916 held indirectly |
| Taylor Andrew LawrenceChief Financial Officer | 590,989 |
| Fain Eric SDirector | 333,441333,441 held indirectly |
| Mack John ProsperDirector | 212,912 |
| Pacitti DavidDirector | 195,556 |
| Aryeh JasonDirector | 118,118 |
| Cleary ChrisDirector | 66,054 |
| Connealy Pamela AnnDirector | 66,038 |
Questions about OBIO
What does Orchestra BioMed Holdings, Inc. do?
Orchestra BioMed Holdings, Inc. is a company in the Health care sector, listed on NASDAQ as OBIO. Its shares trade on NASDAQ under the ticker OBIO.
What is Orchestra BioMed Holdings, Inc.'s net worth?
Orchestra BioMed Holdings, Inc. has a market value (market cap) of $344.4M at the latest share price, and shareholders' equity of $19.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Orchestra BioMed Holdings, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $59M on revenue of $32M.
How much revenue does Orchestra BioMed Holdings, Inc. make?
Over the twelve months to June 30, 2026 Orchestra BioMed Holdings, Inc. reported revenue of $32M. That is 986.1% more than a year earlier.
When did Orchestra BioMed Holdings, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 10, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from November 9, 2026.
When is Orchestra BioMed Holdings, Inc.'s next earnings report?
Orchestra BioMed Holdings, Inc.'s next report was expected around November 9, 2026 and is not on file with the SEC yet.
Similar companies
Compare OBIO with
Follow OBIO
Get an email when Orchestra BioMed Holdings, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Orchestra BioMed Holdings, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.